Herrera Guillermo A, Del Pozo-Yauner Luis, Teng Jiamin, Zeng Chun, Shen Xinggui, Moriyama Takahito, Ramirez Alcantara Veronica, Liu Bing, Turbat-Herrera Elba A
Department of Pathology, College of Medicine, University of South Alabama, Mobile, Alabama, USA.
Department of Physiology and Cell Biology, College of Medicine, University of South Alabama, Mobile, Alabama, USA.
Kidney Int Rep. 2021 Mar 13;6(5):1379-1396. doi: 10.1016/j.ekir.2021.02.014. eCollection 2021 May.
Deciphering the intricacies of the interactions of glomerulopathic Ig light chains with mesangial cells is key to delineate signaling events responsible for the mesangial pathologic alterations that ensue.
Human mesangial cells, caveolin 1 (CAV1), wild type (WT) ,and knockout (KO), were incubated with glomerulopathic light chains purified from the urine of patients with light chain-associated (AL) amyloidosis or light chain deposition disease. Associated signaling events induced by surface interactions of glomerulopathic light chains with caveolins and other membrane proteins, as well as the effect of epigallocatechin-3-gallate (EGCG) on the capacity of mesangial cells to intracellularly process AL light chains were investigated using a variety of techniques, including chemical crosslinking with mass spectroscopy, immunofluorescence, and ultrastructural immunolabeling.
Crosslinking experiments provide evidence suggesting that sortilin-related receptor (SORL1), a transmembrane sorting receptor that regulates cellular trafficking of proteins, is a component of the receptor on mesangial cells for glomerulopathic light chains. Colocalization of glomerulopathic light chains with SORL1 in caveolae and also in lysosomes when light chain internalization occurred, was documented using double immunofluorescence and immunogold labeling ultrastructural techniques. It was found that EGCG directly blocks c-Fos cytoplasmic to nuclei signal translocation after interactions of AL light chains with mesangial cells, resulting in a decrease in amyloid formation.
Our findings document for the first time a role for SORL1 linked to glomerular pathology and signaling events that take place when certain monoclonal light chains interact with mesangial cells. This finding may lead to novel therapies for treating renal injury caused by glomerulopathic light chains.
破解肾小球病性免疫球蛋白轻链与系膜细胞相互作用的复杂机制,是明确导致后续系膜病理改变的信号转导事件的关键。
将人系膜细胞、小窝蛋白1(CAV1)野生型(WT)和敲除型(KO)与从轻链相关(AL)淀粉样变性或轻链沉积病患者尿液中纯化的肾小球病性轻链一起孵育。使用多种技术,包括化学交联质谱分析、免疫荧光和超微结构免疫标记,研究了肾小球病性轻链与小窝蛋白及其他膜蛋白表面相互作用诱导的相关信号转导事件,以及表没食子儿茶素-3-没食子酸酯(EGCG)对系膜细胞细胞内处理AL轻链能力的影响。
交联实验提供的证据表明,sortilin相关受体(SORL1),一种调节蛋白质细胞内运输的跨膜分选受体,是系膜细胞上肾小球病性轻链受体的一个组成部分。利用双重免疫荧光和免疫金标记超微结构技术,记录了肾小球病性轻链与SORL1在小窝以及轻链内化时在溶酶体中的共定位情况。研究发现,EGCG在AL轻链与系膜细胞相互作用后直接阻断c-Fos从细胞质到细胞核的信号转位,导致淀粉样蛋白形成减少。
我们的研究结果首次证明了SORL1在肾小球病理以及某些单克隆轻链与系膜细胞相互作用时发生的信号转导事件中的作用。这一发现可能会带来治疗肾小球病性轻链所致肾损伤的新疗法。